Preferred Medicine is committed to addressing the issues that today’s cancer screening options may not provide the best early detection results, leading to invasive biopsies and unnecessary stress for patients. As a precision oncology company that combines the power of miRNA and AI technologies, Preferred Medicine provides a simple and highly accurate blood test to detect the world’s most common cancers at an early stage.
Our goal is to widen access to cancer screening for all at risk patients - helping to reduce uncertainty and healthcare costs, while improving care, quality of life, and in many cases, saving lives.
CEO / Founder
He leads R&D including clinical studies and deep learning technology development. He is an academic researcher himself and very passionate about finding ways to innovate medical science with cutting-edge technology. He obtained his Ph.D. of Molecular Biophysics and Biochemistry at Yale University, and became a researcher at the Biophysics department of University of California, San Francisco and Howard Hughes Medical Institute.
COO / Founder
He has over 15 years of experience in the fundamental and clinical research field and spent a great amount of time researching neuroscience and cancer diagnosis. He has also managed Post Merger Integration of pharmaceutical companies and new business launches globally. He has a Ph.D. in pharmaceutical science from University of Tokyo, Japan.
Head of Commercial Strategy and
Raees brings over 12 years of experience in commercial leading roles within Diagnostics.
He previously worked for Natera as a Senior Director of Business Development, where he played an integral role in the launch of Panorama.
Raees has a Master of Business Administration from University of Rochester, Simon Graduate School Of Business, NY and B.S in Biochemistry from University of California Riverside, CA.
Ken has over 20 years of experience in the life science industry as an executive, entrepreneur, and investor. He is President and COO of Teon Therapeutics.
He was the CEO of Symic Bio a biopharmaceutical company developing novel extracellular matrix targeting drugs. He also was a founding member and VP of Business Development of TauTona Group, an early-stage life science venture capital fund.
He has a B.S. and M.S. degree from Stanford University in mechanical engineering and is a Kauffman Fellow.
Dr. Seema Ahsan Khan is a Professor of Surgery at the Feinberg School of Medicine at Northwestern University. Her clinical practice includes the surgical therapy of breast cancer and the evaluation and management of women at high risk for breast cancer.
Her current research is focused on the development of novel agents for breast cancer prevention, and on transdermal drug delivery to the breast through the breast skin so as to avoid or reduce the systemic effects associated with oral drug administration.
Dr. Takahiro Ochiya is a Professor of the Department of Molecular and Cellular Medicine at the Tokyo Medical University, Tokyo and an invited researcher of the National Cancer Center Research Institute, Tokyo, Japan.
He works on the development of novel animal models, methods, and strategies to study cancer development and metastasis. Especially on microRNA-based therapy and liquid biopsy in cancer.
He obtained his Ph.D. in 1988 at Osaka University and was a postdoc at La Jolla Cancer Research, CA, USA.
Ramji founded Teiko. bio whose goal is to unlock actionable cellular insights. Prior to Teiko.Bio, he was co-founder, CEO, and chairman of Counsyl, a women’s health genetic screening laboratory. Counsyl screened over 1M prospective parents, mothers-to-be, and women at risk of hereditary cancer. In 2018, Counsyl was acquired by Myriad Genetics, Inc for $375M.
He earned a B.S. in computer science and an M.S. in financial mathematics from Stanford University.
Sign up to be the first to hear any updates